

## Pharmacometabolomics in TB Meningitis – understanding the pharmacokinetic, metabolic, and immune factors associated with anti-TB drug concentrations in cerebrospinal fluid

Jeffrey M. Collins<sup>1</sup>, Maia Kipiani<sup>2,3,4</sup>, Yutong Jin<sup>5</sup>, Ashish A. Sharma<sup>6</sup>, Jeffrey A. Tomalka<sup>6</sup>, Teona Avaliani<sup>2</sup>, Mariam Gujabidze<sup>2</sup>, Tinatin Bakuradze<sup>2</sup>, Shorena Sabanadze<sup>2</sup>, Zaza Avaliani<sup>2,7</sup>, Henry M. Blumberg<sup>1,8</sup>, David Benkeser<sup>5</sup>, Dean P. Jones<sup>1</sup>, Charles Peloquin<sup>9</sup>, Russell R. Kempker<sup>1</sup>.

<sup>1</sup>Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

<sup>2</sup>National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

<sup>3</sup>The University of Georgia, Tbilisi, Georgia

<sup>4</sup>David Tvildiani Medical University, The University of Georgia, Tbilisi, Georgia  
National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

<sup>5</sup>Department of Biostatistics, Rollins School of Public Health of Emory University, Atlanta, Georgia, USA

<sup>6</sup>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

<sup>7</sup>European University, Tbilisi, Georgia

<sup>8</sup>Departments of Epidemiology and Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

<sup>9</sup>Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, Florida, USA.

### \* Correspondence:

Name: Jeffrey Collins, MD, MPH, MSc

Email: [jeffrey.michael.collins@emory.edu](mailto:jeffrey.michael.collins@emory.edu)

Keywords: tuberculosis, meningitis, metabolomics, cytokines, CSF

Running Title: Pharmacometabolomics in TB Meningitis

Article Type: Research Article

1 **Abstract**

2 Poor penetration of many anti-tuberculosis (TB) antibiotics into the central nervous  
3 system (CNS) is thought to be a major driver of morbidity and mortality in TB meningitis  
4 (TBM). While the amount of a particular drug that crosses into the cerebrospinal fluid  
5 (CSF) varies from person to person, little is known about the host factors associated  
6 with interindividual differences in CSF concentrations of anti-TB drugs. In patients  
7 diagnosed with TBM from the country of Georgia (n=17), we investigate the association  
8 between CSF concentrations of anti-TB antibiotics and multiple host factors including  
9 serum drug concentrations and CSF concentrations of metabolites and cytokines. We  
10 found >2-fold differences in CSF concentrations of anti-TB antibiotics from person to  
11 person for all drugs tested including cycloserine, ethambutol, imipenem, isoniazid,  
12 levofloxacin, linezolid, moxifloxacin pyrazinamide, and rifampin. While serum drug  
13 concentrations explained over 40% of the variation in CSF drug concentrations for  
14 cycloserine, isoniazid, linezolid, and pyrazinamide (adjusted  $R^2 > 0.4$ ,  $p < 0.001$  for all),  
15 there was no evidence of an association between serum concentrations of imipenem  
16 and ethambutol and their respective CSF concentrations. CSF concentrations of  
17 carnitines were significantly associated with concentrations of ethambutol and imipenem  
18 ( $q < 0.05$ ), and imipenem was the only antibiotic significantly associated with CSF  
19 cytokine concentrations. These results indicate that there is high interindividual  
20 variability in CSF drug concentrations in patients treated for TBM, which is only partially  
21 explained by differences in serum drug concentrations and not associated with  
22 concentrations of cytokines and chemokines in the CSF.

23

## 24 **Introduction**

25           Tuberculosis meningitis (TBM) is the most lethal manifestation of tuberculosis  
26 (TB) disease, with a mortality rate  $\geq 25\%$  in those with drug susceptible disease and  
27  $>65\%$  in persons with drug resistance.<sup>1,2</sup> Therapeutic options for TBM are more limited  
28 than in other forms of TB due to poor penetration of many anti-TB drugs into the central  
29 nervous system (CNS).<sup>1,3-5</sup> However, the concentration of antibiotics in the CNS can  
30 vary widely by antibiotic and from person to person, indicating certain endotypes exist  
31 that lead to favorable CNS penetration of drugs. While it is generally thought that  
32 meningeal inflammation increases the CNS concentration of antibiotics, there is limited  
33 empirical evidence supporting this concept in TBM.<sup>6</sup> Further, little is known about the  
34 specific inflammatory signaling networks in TBM that may modulate CNS penetration of  
35 anti-TB chemotherapeutic agents. An improved understanding of host responses  
36 associated with CNS penetration of anti-TB drugs could help inform new strategies to  
37 enhance drug delivery to the site of disease in TBM.

38           Recent advances in metabolomics and high-density cytokine measurement allow  
39 for high-resolution immunometabolic profiling of a variety of human samples including  
40 cerebrospinal fluid (CSF).<sup>7</sup> Such profiling allows for simultaneous measurement of over  
41 30 cytokines and thousands of metabolites, including xenobiotics<sup>8</sup> and molecules that  
42 regulate inflammation.<sup>9,10</sup> Combining measurement of these host response molecules  
43 with drug concentrations at the site of disease has the potential to elucidate metabolic  
44 and inflammatory processes that regulate drug concentrations and efficacy in TBM; an  
45 approach termed pharmacometabolomics.<sup>11</sup>

46 In a well characterized population of patients from the country of Georgia  
47 diagnosed and treated for TBM, we integrated data on serum and CSF concentrations  
48 of anti-TB antibiotics<sup>5</sup> and CSF concentrations of metabolites and cytokines.<sup>7</sup> By  
49 integrating these data sets, we sought to address multiple knowledge gaps that  
50 currently exist with regard to antibiotic therapy for TB meningitis as follows: 1) the  
51 degree of interindividual variability in CSF drug concentrations, 2) whether variation in  
52 serum drug concentrations explain the variation in CSF drug concentrations, 3) whether  
53 untargeted metabolomics can be used to accurately measure concentrations of TB  
54 antibiotics in the CNS, and 4) whether individual differences in the CSF milieu of soluble  
55 immunometabolic mediators (i.e. metabolites and cytokines) are associated with CSF  
56 drug concentrations of different anti-TB drugs.

## 57 **RESULTS**

### 58 **Participants**

59 We studied CSF samples from 17 participants with suspected TBM presenting to  
60 the National Center for Tuberculosis and Lung Diseases (NCTLD) (**Table 1**). Among the  
61 17 patients with suspected TBM, five (29%) were microbiologically confirmed while  
62 three (18%) were considered to have probable TBM and nine (53%) were considered to  
63 have possible TBM based on clinical and laboratory criteria.<sup>12,13</sup> The median CSF white  
64 blood cell (WBC) count at diagnosis was 209 cells/mm<sup>3</sup> (IQR 130-286), with 94%  
65 lymphocytes (IQR 85-96), a median glucose of 40 mg/dL (IQR 21-50), and total protein  
66 of 99 mg/dL (IQR 66-132). Antibiotic regimens were selected by treating clinicians  
67 based on NCTLD guidelines and response to treatment as previously reported.<sup>5,14</sup> Five  
68 persons with TBM were deemed to have a poor initial response to treatment, two of

69 whom were diagnosed with multi-drug-resistant (MDR)-TBM based on microbiologic  
70 testing.

### 71 **Variation in CSF Concentrations of Anti-TB Drugs**

72 We first sought to characterize the interindividual variability of anti-TB drug  
73 concentrations in the CSF. As per standard of care for patients hospitalized with TBM at  
74 NCTLD, lumbar punctures were performed at diagnosis (baseline) and approximately 7,  
75 14, and 28 days after TBM treatment initiation and monthly for as long as patients were  
76 hospitalized to follow CSF cell and protein counts in response to treatment.<sup>5,14</sup> Due to  
77 differences between participants in the number of antibiotic doses received at the time  
78 of the baseline CSF sample, only samples obtained  $\geq 7$  days after treatment start were  
79 included in this analysis. Antibiotic concentrations were quantified in the serum and CSF  
80 at each time point either 2 or 6 hours after the most recent antibiotic dose as previously  
81 described.<sup>5</sup> A 2- to 4-fold difference in CSF drug concentrations was found between  
82 participants at 2 hours (**Figure 1A-I**) and 6 hours (**Figure 2A-I**) after the dosing of anti-  
83 TB antibiotics. This was observed across antibiotics, indicating a large amount of  
84 interindividual variability in CSF drug concentrations regardless of the drug used.

85 There are multiple sources of potential interindividual variability in CSF drug  
86 concentrations among patients with TBM including integrity of the blood-brain and  
87 blood-CSF barriers, variability in protein binding, and differential expression of drug  
88 transporters.<sup>15</sup> TB drugs are also known to have large differences in serum  
89 concentration from person to person, which could explain some or all of the variability in  
90 CSF drug concentrations.<sup>16</sup> To examine this possibility, we sought to determine how  
91 well concomitantly collected serum drug concentrations explained the variation in CSF

92 drug concentrations using a mixed effects linear model. We found the relationship  
93 between plasma and CSF drug concentrations varied substantially from drug to drug.  
94 For cycloserine, isoniazid, and linezolid, we calculated an adjusted  $R^2$  of  $>0.5$ ,  
95 suggesting serum drug concentrations explained over 50% of the variability in CSF drug  
96 concentrations (**Figure 3A-C**). For other drugs including pyrazinamide, levofloxacin, and  
97 rifampin, serum drug concentrations explained a statistically significant amount of  
98 variation in CSF concentrations, but the adjusted  $R^2$  values were 0.4, 0.23 and 0.19  
99 respectively (**Figure 3D-F**). For moxifloxacin, imipenem, and ethambutol, serum drug  
100 concentrations were not significantly associated with CSF drug concentrations (**Figure**  
101 **3G-I**).

## 102 **Using Untargeted Metabolomics to measure CSF Drug Concentrations**

103 We performed untargeted high-resolution metabolomics on CSF samples using  
104 combined liquid chromatography-mass spectrometry in dual ionization mode with HILIC  
105 positive and c18 negative chromatography (see Methods for full details). We detected  
106 6,596 metabolic features in positive ionization mode and 9,427 in negative ionization  
107 mode. We then performed a targeted search for molecular features that were within a  
108 mass and retention time error range of 5 ppm and 30 seconds respectively for the M+H  
109 or M-H adducts of anti-TB drugs. This query yielded high confidence matches for  
110 several anti-TB drugs including ethambutol, isoniazid, pyrazinamide, rifampin, linezolid,  
111 imipenem, levofloxacin, and moxifloxacin. We then performed a correlation analysis of  
112 the peak intensity for each annotated metabolite and the antibiotic concentration as  
113 measured using MS/MS and a purified standard curve.<sup>5</sup> We found that the intensity  
114 value for each antibiotic as measured by our untargeted metabolomics platform was

115 strongly correlated with the absolute concentration of most anti-TB antibiotics in the  
116 CSF. Peaks for ethambutol, pyrazinamide, isoniazid, linezolid, and imipenem all  
117 demonstrated a Pearson correlation coefficient of  $>0.7$  when compared with absolute  
118 drug concentrations (**Figure 4A-E**;  $p<0.001$  for all). The peak intensity for moxifloxacin  
119 ( $r=0.53$ ,  $p=0.05$ ) and levofloxacin ( $r=0.45$ ,  $p<0.001$ ), as well as rifampin ( $r=0.48$ ,  
120  $p<0.001$ ), were also significantly correlated with measured CSF concentrations, but the  
121 relationship was less strong than for the other antibiotics studied (**Figure 4F-H**). In the  
122 case of rifampin, this may have been due in part to the relatively low concentration of  
123 this antibiotic in the CSF. These data indicate that untargeted metabolomics can be an  
124 effective method to approximate many anti-TB drug concentrations in biofluids.

#### 125 **Relationship Between CSF Metabolism, Inflammation, and Drug Concentrations**

126 Antibiotic penetration into the CSF is generally thought to be increased when  
127 there is a breakdown in the blood-brain barrier due to meningeal inflammation in  
128 persons with TBM.<sup>17</sup> We therefore sought to mine concomitantly collected high-  
129 resolution metabolomics and cytokine data to determine whether any soluble immune  
130 mediators were associated with CSF drug concentrations. We used mixed effects linear  
131 models to determine which cytokines and metabolites with known chemical identities  
132 were most strongly associated with CSF concentrations of each antibiotic. In **Figure 5**,  
133 we show the metabolites and cytokines significantly associated with the concentration of  
134 at least one antibiotic using a false discovery correction of  $q<0.05$ . We found that  
135 carnitines were significantly associated with CSF concentrations of ethambutol and  
136 imipenem at  $q<0.05$ , as well as isoniazid, linezolid, pyrazinamide, and rifampin at an  
137 unadjusted  $p<0.05$ . However, the directionality of the association was inconsistent.

138 While increased CSF concentrations of carnitines were associated with increased  
139 concentrations of ethambutol and imipenem, they were associated with lower CSF  
140 concentrations of isoniazid, linezolid, pyrazinamide, and rifampin. This suggests that  
141 different metabolic states in the CNS may be associated with increased drug  
142 penetration for certain classes of antibiotics while decreasing CSF drug concentrations  
143 for others.

144 There were few significant associations between cytokine and antibiotic  
145 concentrations in the CNS. Increased concentrations of pro-inflammatory cytokines and  
146 chemokines including TNF- $\alpha$ , MCP-3, IL-6, IL-18, and IFN- $\gamma$  were associated with  
147 increased concentrations of imipenem, but otherwise had little relationship to CSF  
148 antibiotic concentrations. The only exception was IL-6, which was significantly  
149 associated with CSF ethambutol concentrations. These data indicate that an  
150 inflammatory CSF milieu had minimal impact on CSF concentrations anti-TB antibiotics.

151

## 152 **DISCUSSION**

153 In this TBM pharmacometabolomics study, we show there is significant  
154 interindividual variability in CSF concentrations of anti-TB antibiotics. We further show  
155 that differences in serum drug concentrations account for much of the variability in CSF  
156 concentrations of linezolid, isoniazid, and cycloserine, but have a less strong  
157 relationship with CSF concentrations of imipenem, rifampin, moxifloxacin, and  
158 ethambutol. Finally, we demonstrate that CSF drug concentrations may be affected by  
159 the CSF metabolic milieu and have little association with concentrations of  
160 proinflammatory cytokines and chemokines. Together, these data show that a complex



161 mix of factors contribute to CSF concentrations of anti-TB antibiotics. For many  
162 antibiotics, factors such as CNS inflammation and serum concentrations, which are  
163 traditionally thought to be primary drivers of drug concentrations in the CNS, may play  
164 only a minor role.

165 While serum concentrations of anti-TB drugs are known to vary widely from  
166 person to person,<sup>16</sup> we show equally wide variability in CSF drug concentrations in  
167 those treated for TBM. Across the study population we found greater than 2-fold  
168 differences in CSF concentrations of all anti-TB drugs studied. This was true both two  
169 and six hours after the dose of each drug. Such variability in the CSF concentrations of  
170 anti-TB drugs has been shown in other studies, most notably among 237 patients (>700  
171 CSF samples) included in a pharmacology sub study evaluating rifampin, isoniazid, and  
172 levofloxacin CSF concentrations.<sup>18</sup> The substantial variation in CSF concentrations  
173 among study participants was evidenced by large 95% confidence intervals for both  
174  $C_{max}$  and AUC parameters.<sup>18</sup> Furthermore, interpatient variability in CSF rifampin<sup>19</sup> and  
175 fluoroquinolone<sup>20</sup> concentrations have been demonstrated in clinical trial dose finding  
176 and drug comparison studies, respectively. What has been less studied, is clinical or  
177 laboratory predictors of CSF drug concentrations. We found that serum concentrations  
178 are poorly predictive of CSF concentrations for many drugs including imipenem,  
179 rifampin, moxifloxacin, and ethambutol. Using the plasma rifampin AUC<sub>0-24</sub> parameter,  
180 Dian et al, found a high correlation between plasma and CSF rifampin concentrations  
181 (Spearman's  $\rho$  0.7,  $p < .01$ ).<sup>19</sup> A better understanding of predictors of CSF drug  
182 penetration is needed to help both understand the underlying mechanisms of drugs

183 reaching the site of disease and also to identify clinically useful markers to help guide  
184 optimal drug dosing in TBM.

185         This study provides evidence that untargeted, high-resolution metabolomics can  
186 be an accurate way to capture drug concentrations of multiple anti-TB drugs including  
187 imipenem, ethambutol, isoniazid, linezolid, and pyrazinamide. This result is supported  
188 by studies showing untargeted metabolomics can also be an accurate way to capture  
189 exposure to xenobiotics in the environment.<sup>8</sup> The ability to accurately quantify drug  
190 concentrations as part of an untargeted metabolomics platform is likely to create  
191 additional opportunities to understand drug concentrations and pharmacokinetics in the  
192 context of broader measurement of host metabolism. Understanding broad host  
193 metabolic responses to drugs, termed “pharmacometabolomics”, is an emerging area of  
194 study with great potential to improve our understanding of heterogeneous host responses  
195 to medications including antibiotics and enhance personalized medicine.<sup>11</sup> However, a  
196 limitation of the approach has been the need to separately perform targeted  
197 quantification of drugs and untargeted metabolomics. Our findings suggest that in many  
198 cases, important insights in pharmacometabolomics could be obtained from untargeted  
199 metabolomics data alone.

200         By simultaneously collecting pharmacology, metabolomics, and cytokine data in  
201 the present study, we were able to examine which soluble immune and metabolic  
202 mediators in CSF are associated with improved CNS penetration of TB drugs. The  
203 association between CSF concentrations of multiple antibiotics and carnitines suggests  
204 that a metabolic milieu with increased oxidative phosphorylation may impact antibiotic  
205 penetration in the CNS. Increased carnitines in the CSF, which transport fatty acids

206 from the cytosol into mitochondria to be oxidized, may reflect improved cellular function  
207 and lower levels of glycolysis, which tends to produce greater inflammatory signaling in  
208 immune cells.<sup>9,21,22</sup> Historically, greater inflammation in the CNS has been thought to be  
209 a catalyst for drug penetration across blood-brain and blood-CSF barriers.<sup>17</sup> The  
210 present study found little relationship between CSF drug concentrations and pro-  
211 inflammatory cytokines. While elevated CSF concentrations of cytokines does not  
212 necessarily indicate increased meningeal inflammation, the findings do suggest that the  
213 relationship between CSF drug concentrations and inflammation is minimal. This is  
214 supported by prior work from our group, which indicated CSF concentrations of anti-TB  
215 drugs are roughly equal early in the course TBM treatment versus two or more months  
216 after treatment start, when meningeal inflammation would be expected to decrease.<sup>5</sup>  
217 However, another explanation for these findings is that the CSF milieu remains highly  
218 inflammatory months after treatment start,<sup>7</sup> which could mean CNS drug penetration is  
219 enhanced for an extended period of time.

220         This study is subject to several limitations. The small sample size of persons with  
221 TBM and low number of microbiologically confirmed cases from a single geographic  
222 region available for analysis in this study may limit generalizability. Further, the  
223 robustness of statistical inferences from such a small sample is limited. Though we  
224 demonstrate a strong association between CSF concentrations of multiple metabolites  
225 and concentrations of anti-TB drugs, the observational nature of the study precludes us  
226 from establishing a causal relationship. In future studies it will be important to evaluate  
227 the links between key metabolites and CSF drug penetration using animal models of  
228 TBM and larger, diverse human cohorts. Enhancing our understanding of how soluble

229 mediators in the CNS impact drug penetration may lead to therapies that enhance drug  
230 delivery to this area or personalized dosing regimens for individual patients.

231 Overall, this study shows the interindividual variation in CSF drug concentrations  
232 among persons with TBM is high and potentially linked to the metabolic milieu of the  
233 CSF. Serum drug concentrations are only weakly associated with CSF concentrations  
234 for some drugs, and the amount of inflammation in the CSF appears to have only a  
235 minor role in enhancing drug penetration. Our results provide insight into the factors that  
236 impact CSF drug concentrations in TBM and indicate that improved understanding of  
237 the host metabolic response could provide targets to enhance drug delivery.

238

## 239 **MATERIAL AND METHODS**

### 240 **Setting and Participants with TBM**

241 Persons with TBM were enrolled from the National Center for Tuberculosis and  
242 Lung Diseases (NCTLD) in Tbilisi, Georgia as part of a clinical pharmacology study  
243 evaluating the penetration of anti-TB drugs into the CNS.<sup>5</sup> Patients aged  $\geq 16$  years  
244 treated in the NCTLD adult TBM ward from January 2018 to December 2019 were  
245 eligible for inclusion. All patients suspected of having TBM underwent a lumbar  
246 puncture; acid-fast bacilli (AFB) staining, liquid and solid culture, and Xpert MTB/RIF  
247 assay were performed on CSF. As per standard of care for patients hospitalized with  
248 TBM at NCTLD, lumbar punctures were performed at approximately 7, 14, and 28 days  
249 after TBM treatment initiation and monthly for as long as patients were hospitalized to  
250 follow CSF cell and protein counts in response to treatment.<sup>5,14</sup> Treatment regimens  
251 were selected by treating clinicians based on treatment history, comorbidities, and drug

252 susceptibility results when available.<sup>14</sup> All patients also received a 6–8-week course of  
253 dexamethasone (400-1200 mg). Written informed consent was obtained from all study  
254 participants, and study approval was obtained from the institutional review boards of  
255 Emory University and the NCTLD.

## 256 **Sample Collection and Drug Quantification**

257 Blood samples were collected at 2 and 6 hours after drug administration at each  
258 timepoint. For CSF collection, 3 mL was collected at each time point, alternating  
259 between 2 and 6 hours after drug administration to capture early and delayed drug  
260 penetration into the CSF. All centrifuged blood as well as CSF samples were stored at –  
261 80°C at the NCTLD until shipped to the Infectious Diseases Pharmacokinetic Laboratory  
262 at the University of Florida, where drug concentrations were quantified. Total  
263 concentrations of each drug were measured using validated liquid chromatography  
264 tandem mass spectrometry assays. The assays were validated for human plasma, and  
265 cross checked for matrix effects using artificial CSF. The analyses were performed on  
266 Thermo Scientific TSQ Endura or TSQ Quantum Ultra mass spectrometers.

## 267 **Metabolomics analysis**

268 De-identified CSF samples were randomized by a computer-generated list into  
269 blocks of 40 samples prior to transfer to the analytical laboratory where personnel were  
270 blinded to clinical and demographic data. Thawed CSF (65 µL) was treated with 130 µL  
271 acetonitrile (2:1, v/v) containing an internal isotopic standard mixture (3.5 µL/sample),  
272 as previously described.<sup>23</sup> Samples were centrifuged and supernatants were analyzed  
273 using an Orbitrap Q Exactive Mass Spectrometer (Thermo Scientific, San Jose, CA,  
274 USA) with dual HILIC positive and c18 negative liquid chromatography (Higgins

275 Analytical, Targa, Mountain View, CA, USA, 2.1 x 10 cm) with a formic acid/acetonitrile  
276 gradient. The high-resolution mass spectrometer was operated over a scan range of 85  
277 to 1275 mass/charge ( $m/z$ ).<sup>24</sup> Data were extracted and aligned using apLCMS<sup>25</sup> and  
278 xMSanalyzer<sup>26</sup> with each feature defined by specific  $m/z$  value, retention time, and  
279 integrated ion intensity.<sup>24</sup> Three technical replicates were performed for each CSF  
280 sample and intensity values were median summarized.

### 281 **Cytokine detection**

282 The commercially available U-PLEX assay by Meso Scale Discovery (MSD) was  
283 used for CSF cytokine detection. This assay allows for the evaluation of multiplexed  
284 biomarkers by using custom made U-PLEX sandwich antibodies with a SULFO-TAG  
285 conjugated antibody and electrochemiluminescence (ECL) detection. Direct quantitation  
286 of cytokines was performed using standard curves generated by 4-fold serial dilutions of  
287 standard calibrators provided by MSD. Plates were read on the QuickPlex SQ 120 using  
288 Methodical Mind<sup>TM</sup> software and plate data analyzed using Discovery Workbench<sup>TM</sup>  
289 software (MSD).<sup>27,28</sup>

### 290 **Statistical Analysis**

291 Descriptive statistics were provided for baseline characteristics, and the  
292 concentrations of anti-TB antibiotics in patients' CSF were summarized for each drug at  
293 both 2-hour and 6-hour time points following the most recent antibiotic dose. We applied  
294 a linear mixed regression model, adjusting for sampling time (2 or 6 hours),<sup>27</sup> and  
295 reported the adjusted R-squared values of each pairwise comparison of models,  
296 whether they included or excluded serum concentration<sup>29</sup>. Similarly, to determine  
297 associations between CSF drug concentrations and metabolite and cytokine

298 concentrations, we applied a linear mixed regression model, adjusting for sampling time  
299 (2 or 6 hours), and reported the adjusted R-squared values of each pairwise  
300 comparison of models, whether they included or excluded the concentration of a  
301 particular metabolite or cytokine<sup>29</sup>. A false discovery rate (FDR) correction was  
302 employed to account for multiple comparisons when examining associations between  
303 anti-TB drugs and metabolites and cytokines.<sup>28</sup> All analyses were conducted using R  
304 version 4.2.1.

305

### 306 **Acknowledgments**

307 The authors thank the physicians, nurses, and staff at the NCTLD in Tbilisi, Georgia,  
308 who provided care for the patients with TBM included in this study. Additionally, the  
309 authors are thankful for study participants with tuberculosis meningitis who were willing  
310 to participate in the study and help contribute meaningful data that may help future  
311 patients with the same illness.

312

### 313 **Conflict of Interest**

314 The authors declare that the research was conducted in the absence of any commercial  
315 or financial relationships that could be construed as a potential conflict of interest.

316

### 317 **Funding**

318 This work was supported by grants from the National Institutes of Health (NIH) and  
319 National Institute of Allergy and Infectious Diseases [R03AI139871, K23AI103044,

320 K23AI144040, P30AI168386, P30AI050409]; NIH Fogarty International Center  
321 [D43TW007124]; and NIH National Center for Advancing Translational Science  
322 [UL1TR002378], Bethesda, MD, USA. The study sponsors had no role in the study  
323 design; in the collection, analysis, and interpretation of data; in the writing of the  
324 manuscript; or in the decision to submit the manuscript for publication.

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342



343 **References**

- 344 1. Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. *Nat Rev Neurol.*  
345 2017;13(10):581-598.
- 346 2. Evans EE, Avaliani T, Gujabidze M, et al. Long term outcomes of patients with  
347 tuberculous meningitis: The impact of drug resistance. *PLoS One.*  
348 2022;17(6):e0270201.
- 349 3. Heemskerk AD, Nguyen MTH, Dang HTM, et al. Clinical Outcomes of Patients With  
350 Drug-Resistant Tuberculous Meningitis Treated With an Intensified Antituberculosis  
351 Regimen. *Clin Infect Dis.* 2017;65(1):20-28.
- 352 4. Vinnard C, King L, Munsiff S, et al. Long-term Mortality of Patients With Tuberculous  
353 Meningitis in New York City: A Cohort Study. *Clin Infect Dis.* 2017;64(4):401-407.
- 354 5. Kempker RR, Smith AGC, Avaliani T, et al. Cycloserine and Linezolid for  
355 Tuberculosis Meningitis: Pharmacokinetic Evidence of Potential Usefulness. *Clin Infect*  
356 *Dis.* 2022;75(4):682-689.
- 357 6. Nau R, Seele J, Djukic M, Eiffert H. Pharmacokinetics and pharmacodynamics of  
358 antibiotics in central nervous system infections. *Curr Opin Infect Dis.* 2018;31(1):57-68.
- 359 7. Tomalka J, Sharma A, Smith AGC, et al. Combined cerebrospinal fluid metabolomic  
360 and cytokine profiling in tuberculosis meningitis reveals robust and prolonged changes  
361 in immunometabolic networks. *Tuberculosis.* 2023. *In press.*
- 362 8. Liu KH, Lee CM, Singer G, et al. Large scale enzyme based xenobiotic identification  
363 for exposomics. *Nat Commun.* 2021;12(1):5418.
- 364 9. Collins JM, Jones DP, Sharma A, et al. TCA cycle remodeling drives proinflammatory  
365 signaling in humans with pulmonary tuberculosis. *PLoS Pathog.* 2021;17(9):e1009941.

- 366 10. Collins JM, Siddiqa A, Jones DP, et al. Tryptophan catabolism reflects disease  
367 activity in human tuberculosis. *JCI Insight*. 2020;5(10).
- 368 11. Beger RD, Schmidt MA, Kaddurah-Daouk R. Current Concepts in  
369 Pharmacometabolomics, Biomarker Discovery, and Precision Medicine. *Metabolites*.  
370 2020;10(4).
- 371 12. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case  
372 definition for use in clinical research. *Lancet Infect Dis*. 2010;10(11):803-812.
- 373 13. Marais BJ, Heemskerk AD, Marais SS, et al. Standardized Methods for Enhanced  
374 Quality and Comparability of Tuberculous Meningitis Studies. *Clin Infect Dis*.  
375 2017;64(4):501-509.
- 376 14. Smith AGC, Gujabidze M, Avaliani T, et al. Clinical outcomes among patients with  
377 tuberculous meningitis receiving intensified treatment regimens. *Int J Tuberc Lung Dis*.  
378 2021;25(8):632-639.
- 379 15. Dian S, Ganiem AR, van Laarhoven A. Central nervous system tuberculosis. *Curr*  
380 *Opin Neurol*. 2021;34(3):396-402.
- 381 16. Peloquin C. The Role of Therapeutic Drug Monitoring in Mycobacterial Infections.  
382 *Microbiol Spectr*. 2017;5(1).
- 383 17. Haddad N, Carr M, Balian S, et al. The Blood-Brain Barrier and  
384 Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of  
385 Central Nervous System Infections in Adults. *Antibiotics (Basel)*. 2022;11(12).
- 386 18. Ding J, Thuy Thuong Thuong N, Pham TV, et al. Pharmacokinetics and  
387 Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis.  
388 *Clin Pharmacol Ther*. 2020;107(4):1023-1033.

- 389 19. Dian S, Yunivita V, Ganiem AR, et al. Double-Blind, Randomized, Placebo-  
390 Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for  
391 Tuberculous Meningitis. *Antimicrob Agents Chemother.* 2018;62(12).
- 392 20. Thwaites GE, Bhavnani SM, Chau TT, et al. Randomized pharmacokinetic and  
393 pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis.  
394 *Antimicrob Agents Chemother.* 2011;55(7):3244-3253.
- 395 21. Gleeson LE, Sheedy FJ, Palsson-McDermott EM, et al. Cutting Edge:  
396 *Mycobacterium tuberculosis* Induces Aerobic Glycolysis in Human Alveolar  
397 Macrophages That Is Required for Control of Intracellular Bacillary Replication. *J*  
398 *Immunol.* 2016;196(6):2444-2449.
- 399 22. Olson GS, Murray TA, Jahn AN, et al. Type I interferon decreases macrophage  
400 energy metabolism during mycobacterial infection. *Cell Rep.* 2021;35(9):109195.
- 401 23. Soltow QA, Strobel FH, Mansfield KG, Wachtman L, Park Y, Jones DP. High-  
402 performance metabolic profiling with dual chromatography-Fourier-transform mass  
403 spectrometry (DC-FTMS) for study of the exposome. *Metabolomics.* 2013;9(1  
404 Suppl):S132-143.
- 405 24. Go YM, Walker DI, Liang Y, et al. Reference Standardization for Mass Spectrometry  
406 and High-Resolution Metabolomics Applications to Exposome Research. *Toxicol Sci.*  
407 2015;148(2):531-542.
- 408 25. Yu T, Park Y, Johnson JM, Jones DP. apLCMS--adaptive processing of high-  
409 resolution LC/MS data. *Bioinformatics (Oxford, England).* 2009;25(15):1930-1936.

410 26. Uppal K, Soltow QA, Strobel FH, et al. xMSAnalyzer: automated pipeline for  
411 improved feature detection and downstream analysis of large-scale, non-targeted  
412 metabolomics data. *BMC Bioinformatics*. 2013;14:15.

413 27. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses  
414 for RNA-sequencing and microarray studies. *Nucleic acids research*. 2015;43(7):e47.

415 28. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance  
416 testing. *Statistics in medicine*. 1990;9(7):811-818.

417 29. Nagelkerke NJD. A note on a general definition of the coefficient of determination.  
418 *Biometrika*. 1991;78(3):691-692.

419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432

433 **Tables and Figure Legends (Figure files submitted separately)**

434 **Table 1**

	TB meningitis (n=17)
Age, median (IQR)	36 (31-44)
Female sex, n (%)	9 (53)
TB meningitis diagnostic category, n (%)	
Definite (microbiologically confirmed)	5 (29)
Probable	3 (18)
Possible	9 (53)
CSF total WBC, median (IQR)	209 (130-286)
% Lymphocytes, median (IQR)	94 (85-96)
% Neutrophils, median (IQR)	5 (2-8)
TB meningitis grade, n (%)	
Grade 1	8 (47)
Grade 2	9 (53)
Grade 3	0 (0)

435

436

437

438

439

440

441

442

443

444 **Figure 1** – Boxplots depicting median cerebrospinal fluid concentrations of anti-TB  
445 antibiotics 2 hours after the most recent antibiotic dose for 17 study participants: (A)  
446 cycloserine, (B) ethambutol, (C) imipenem, (D) isoniazid, (E) levofloxacin, (F) linezolid,  
447 (G) moxifloxacin, (H) pyrazinamide, and (I) rifampin.

448

449 **Figure 2** – Boxplots depicting median cerebrospinal fluid concentrations of anti-TB  
450 antibiotics 6 hours after the most recent antibiotic dose for 17 study participants: (A)  
451 cycloserine, (B) ethambutol, (C) imipenem, (D) isoniazid, (E) levofloxacin, (F) linezolid,  
452 (G) moxifloxacin, (H) pyrazinamide, and (I) rifampin.

453

454 **Figure 3** – Scatter plots with fitted regression lines depicting the relationship between  
455 serum and cerebrospinal fluid concentrations of anti-TB drugs: (A) cycloserine, (B)  
456 isoniazid, (C) linezolid, (D) pyrazinamide, (E) levofloxacin, (F) rifampin, (G)  
457 moxifloxacin, (H) imipenem, and (I) ethambutol. For each figure,  $r$  represents the  
458 correlation coefficient with corresponding  $p$ -value. The adjusted  $R^2$  was calculated using  
459 a mixed effects linear model, adjusting for sampling time (2 or 6 hours), with  $p$ -values  
460 derived from the pairwise comparison of models including and excluding the serum  
461 concentration of each drug.

462

463










464

465










466 **Figure 4** – Scatter plots with fitted regression lines depicting the relationship between  
467 cerebrospinal fluid concentrations of anti-TB drugs and their mass spectrometry  
468 intensity value as measured on the untargeted metabolomics platform: (A) ethambutol,  
469 (B) isoniazid, (C) linezolid, (D) imipenem, (E) pyrazinamide, (F) moxifloxacin, (G)  
470 rifampin, and (H) levofloxacin. For each figure,  $r$  and  $p$  values are based on the Pearson  
471 correlation coefficient for each drug.










472

473 **Figure 5** – The bubble plots represent the adjusted  $R^2$  values measuring the  
474 association between anti-TB drug concentrations and soluble immune mediators  
475 (metabolites, cytokines, and chemokines) in the cerebrospinal fluid. The color scale for  
476 each dot represents the adjusted  $R^2$  value and dot size represents the  $-\log P$  value for  
477 each association.









Participant ID

- T1
- T17
- T31
- T32
- T33
- T48
- T49
- T50
- T51
- T55
- T64
- T65
- T66
- T67
- T68
- T69
- T70

